{ "@graph": [    { "@id": "http://linked.opendata.cz/resource/ATC/L",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" , "@language" : "en" } ,        { "@value" : "Cytostatika a imunomodula\u010Dn\u00ED l\u00E9\u010Diva" , "@language" : "cs" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "L" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/L02",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "ENDOCRINE THERAPY" , "@language" : "en" } ,        { "@value" : "Hormon\u00E1ln\u00ED l\u00E9\u010Diva pou\u017E\u00EDvan\u00E1 v onkologii" , "@language" : "cs" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "L02" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/L02B",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "HORMONE ANTAGONISTS AND RELATED AGENTS" , "@language" : "en" } ,        { "@value" : "Antagonist\u00E9 hormon\u016F a p\u0159\u00EDbuzn\u00E1 l\u00E9\u010Diva" , "@language" : "cs" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "L02B" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/L02BG",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "Enzyme inhibitors" , "@language" : "en" } ,        { "@value" : "Enzymov\u00E9 inhibitory" , "@language" : "cs" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "L02BG" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/L02BG04",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://www.w3.org/2004/02/skos/core#broaderTransitive" : [ "http://linked.opendata.cz/resource/ATC/L" ,        "http://linked.opendata.cz/resource/ATC/L02" ,        "http://linked.opendata.cz/resource/ATC/L02B" ,        "http://linked.opendata.cz/resource/ATC/L02BG" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "Letrozole" , "@language" : "en" } ,        { "@value" : "Letrozol" , "@language" : "cs" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "L02BG04" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ndfrt/disease/N0000000999",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/DiseaseOrFinding" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Drug hypersensitivity" , "@language" : "en" } ,        { "@value" : "L\u00E9kov\u00E1 alergie" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ndfrt/disease/N0000010195",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/DiseaseOrFinding" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "T\u011Bhotenstv\u00ED" , "@language" : "cs" } ,        { "@value" : "Pregnancy" , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/ingredient/M0184835",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/Ingredient" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Letrozole" , "@language" : "en" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/contraindicatedWith" : [ "http://linked.opendata.cz/resource/ndfrt/disease/N0000010195" ,        "http://linked.opendata.cz/resource/ndfrt/disease/N0000000999" ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product/NINIVET-2-5-MG-POTAHOVANE-TABLETY",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProduct" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasActiveIngredient" : [ "http://linked.opendata.cz/resource/drug-encyclopedia/ingredient/M0184835" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "NINIVET 2,5 MG POTAHOVAN\u00C9 TABLETY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/L02BG04" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasMedicinalProductPackaging" : [ "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0151046" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0151045" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0151044" ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0151044",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "NINIVET 2,5 MG POTAHOVAN\u00C9 TABLETY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/L02BG04" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "CYTOSTATICA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC127819_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "30" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "2.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "Adjuvantn\u00ED l\u00E9\u010Dba prim\u00E1rn\u00EDho karcinomu prsu u postmenopauz\u00E1ln\u00EDch \u017Een s\u00A0pozitivn\u00EDmi hormon\u00E1ln\u00EDmi receptory.\nProdlou\u017Een\u00E1 adjuvantn\u00ED l\u00E9\u010Dba hormon\u00E1ln\u011B\u2011dependentn\u00EDho prim\u00E1rn\u00EDho karcinomu prsu u postmenopauz\u00E1ln\u00EDch \u017Een, kter\u00E9 jsou po dobu 5\u00A0let podrobeny standardn\u00ED adjuvantn\u00ED l\u00E9\u010Db\u011B tamoxifenem.\nL\u00E9\u010Dba prvn\u00ED linie u pokro\u010Dil\u00E9ho st\u00E1dia hormon\u00E1ln\u011B\u2011dependentn\u00EDho karcinomu prsu u postmenopauz\u00E1ln\u00EDch \u017Een.\nL\u00E9\u010Dba pokro\u010Dil\u00E9ho st\u00E1dia karcinomu prsu po recidiv\u011B nebo p\u0159i dal\u0161\u00EDm r\u016Fstu n\u00E1doru u \u017Een v\u00A0p\u0159irozen\u011B nebo um\u011Ble vyvolan\u00E9 postmenopauze, kter\u00E9 byly p\u0159edt\u00EDm l\u00E9\u010Deny antiestrogeny.\nU pacientek s\u00A0hormon\u00E1ln\u011B\u2011independentn\u00EDm karcinomem prsu nebyl \u00FA\u010Dinek letrozolu prok\u00E1z\u00E1n.\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasResumedMarketingDate" : [ { "@value" : "2012-07-31" , "@type" : "http://www.w3.org/2001/XMLSchema#date" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasMaximalPrice" : [ { "@value" : 2278.6298828125 , "@type" : "http://www.w3.org/2001/XMLSchema#float" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasReimbursementAmount" : [ { "@value" : 2278.639892578125 , "@type" : "http://www.w3.org/2001/XMLSchema#float" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL FLM 30X2.5MG" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0151046",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "NINIVET 2,5 MG POTAHOVAN\u00C9 TABLETY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/L02BG04" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "CYTOSTATICA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC127819_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "10" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "2.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "Adjuvantn\u00ED l\u00E9\u010Dba prim\u00E1rn\u00EDho karcinomu prsu u postmenopauz\u00E1ln\u00EDch \u017Een s\u00A0pozitivn\u00EDmi hormon\u00E1ln\u00EDmi receptory.\nProdlou\u017Een\u00E1 adjuvantn\u00ED l\u00E9\u010Dba hormon\u00E1ln\u011B\u2011dependentn\u00EDho prim\u00E1rn\u00EDho karcinomu prsu u postmenopauz\u00E1ln\u00EDch \u017Een, kter\u00E9 jsou po dobu 5\u00A0let podrobeny standardn\u00ED adjuvantn\u00ED l\u00E9\u010Db\u011B tamoxifenem.\nL\u00E9\u010Dba prvn\u00ED linie u pokro\u010Dil\u00E9ho st\u00E1dia hormon\u00E1ln\u011B\u2011dependentn\u00EDho karcinomu prsu u postmenopauz\u00E1ln\u00EDch \u017Een.\nL\u00E9\u010Dba pokro\u010Dil\u00E9ho st\u00E1dia karcinomu prsu po recidiv\u011B nebo p\u0159i dal\u0161\u00EDm r\u016Fstu n\u00E1doru u \u017Een v\u00A0p\u0159irozen\u011B nebo um\u011Ble vyvolan\u00E9 postmenopauze, kter\u00E9 byly p\u0159edt\u00EDm l\u00E9\u010Deny antiestrogeny.\nU pacientek s\u00A0hormon\u00E1ln\u011B\u2011independentn\u00EDm karcinomem prsu nebyl \u00FA\u010Dinek letrozolu prok\u00E1z\u00E1n.\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL FLM 10X2.5MG" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0151045",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "NINIVET 2,5 MG POTAHOVAN\u00C9 TABLETY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/L02BG04" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "CYTOSTATICA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC127819_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "100" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "2.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "Adjuvantn\u00ED l\u00E9\u010Dba prim\u00E1rn\u00EDho karcinomu prsu u postmenopauz\u00E1ln\u00EDch \u017Een s\u00A0pozitivn\u00EDmi hormon\u00E1ln\u00EDmi receptory.\nProdlou\u017Een\u00E1 adjuvantn\u00ED l\u00E9\u010Dba hormon\u00E1ln\u011B\u2011dependentn\u00EDho prim\u00E1rn\u00EDho karcinomu prsu u postmenopauz\u00E1ln\u00EDch \u017Een, kter\u00E9 jsou po dobu 5\u00A0let podrobeny standardn\u00ED adjuvantn\u00ED l\u00E9\u010Db\u011B tamoxifenem.\nL\u00E9\u010Dba prvn\u00ED linie u pokro\u010Dil\u00E9ho st\u00E1dia hormon\u00E1ln\u011B\u2011dependentn\u00EDho karcinomu prsu u postmenopauz\u00E1ln\u00EDch \u017Een.\nL\u00E9\u010Dba pokro\u010Dil\u00E9ho st\u00E1dia karcinomu prsu po recidiv\u011B nebo p\u0159i dal\u0161\u00EDm r\u016Fstu n\u00E1doru u \u017Een v\u00A0p\u0159irozen\u011B nebo um\u011Ble vyvolan\u00E9 postmenopauze, kter\u00E9 byly p\u0159edt\u00EDm l\u00E9\u010Deny antiestrogeny.\nU pacientek s\u00A0hormon\u00E1ln\u011B\u2011independentn\u00EDm karcinomem prsu nebyl \u00FA\u010Dinek letrozolu prok\u00E1z\u00E1n.\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL FLM 100X2.5MG" , "@language" : "cs" } ] }] }